Medications Containing Pimecrolimus: Comprehensive Overview & Safety Insights

Most recent label update in this list Oct 28, 2025checked dailysee data sync status

Drugs that contain pimecrolimus →. Here you'll find every formulation of pimecrolimus, including dose forms, key warnings, common side effects, and pregnancy/lactation guidance. Each drug has a patient overview plus an in‑depth drug insert. The list is refreshed weekly and ordered by current user interest. Always consult a healthcare professional before taking or switching medications.

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

If you are a consumer or patient please visit this version.

Drug safety and usage table for patients and healthcare providers. The numeric badges in each row show how many warnings, pregnancy/lactation notes, and side‑effects are listed inside the expandable details panel.
		Warnings	Pregnancy lactation	Side effects	Trend
Pimecrolimus Rx cream Oceanside Pharmaceuticals	Popularity – score 100 out of 100 (most-viewed drug)	7 warnings	2 pregnancy and lactation warnings	8 side effects	Trend: fell 18% over 11 months; peaks in May, Aug, Oct, Nov, Feb.
Pimecrolimus® · First marketed 2018 · Label last revised September 30, 2020View full label details → Warnings The long-term safety of topical calcineurin inhibitors has not been established. There have been rare cases of malignancy (e.g., skin and lymphoma) reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. You should avoid continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group, and limit application to areas affected by atopic dermatitis. Pimecrolimus Cream, 1% is not recommended for use in children under 2 years of age. This medication should not be used in immunocompromised adults and children, including those on systemic immunosuppressive medications. Please avoid using this treatment on malignant or pre-malignant skin conditions, as these can appear as dermatitis. This medication should not be used in patients with Netherton’s Syndrome or skin diseases that may lead to increased systemic absorption. Pregnancy & Lactation You should use Pimecrolimus Cream, 1% during pregnancy only if the potential benefits outweigh the potential risks to your fetus. You will need to decide whether to stop nursing or to discontinue the drug, considering how important the medication is for you. Side Effects You may experience a burning sensation at the application site. You might have a headache. You could develop nasopharyngitis. Coughing may occur. You may catch the flu. You might experience a fever. You could be at risk for a viral infection. In rare cases, there may be occurrences of malignancy, such as skin cancer or lymphoma. Warnings long-term safety of topical calcineurin inhibitors has not been established rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1% continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided and application limited to areas of involvement with atopic dermatitis Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis should not be used in patients with Netherton’s Syndrome or skin diseases with a potential for increased systemic absorption Pregnancy & Lactation Pimecrolimus Cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Side Effects application site burning headache nasopharyngitis cough influenza pyrexia viral infection rare cases of malignancy (e.g., skin and lymphoma)
Pimecrolimus Rx cream Glenmark Pharmaceuticals Inc. , USA	Popularity – score 100 out of 100 (most-viewed drug)	7 warnings	2 pregnancy and lactation warnings	8 side effects	Trend: fell 18% over 11 months; peaks in May, Aug, Oct, Nov, Feb.
Pimecrolimus® · First marketed 2019 · Label last revised October 28, 2025View full label details → Warnings The long-term safety of topical calcineurin inhibitors has not been established, so it's important to be cautious. There have been rare reports of malignancy (such as skin cancer and lymphoma) in patients treated with topical calcineurin inhibitors, including pimecrolimus cream, 1%. You should avoid continuous long-term use of topical calcineurin inhibitors, including pimecrolimus cream, 1%, in any age group, and limit application to areas affected by atopic dermatitis. Pimecrolimus cream, 1% is not recommended for use in children under 2 years of age. This medication should not be used in immunocompromised adults and children, including those on systemic immunosuppressive medications. Please avoid using this treatment on malignant or pre-malignant skin conditions, as these can appear similar to dermatitis. You should not use this medication if you have Netherton’s Syndrome or skin diseases that may lead to increased systemic absorption. Pregnancy & Lactation You should use pimecrolimus cream, 1%, during pregnancy only if the potential benefits outweigh the potential risks to your fetus. You and your healthcare provider should decide whether to continue nursing or to stop the medication, considering how important the drug is for you. Side Effects You may experience a burning sensation at the application site. You might have a headache. You could develop nasopharyngitis. Coughing may occur. You may catch the flu. You might experience a fever. You could be at risk for a viral infection. In rare cases, there may be a risk of malignancy, such as skin cancer or lymphoma. Warnings long-term safety of topical calcineurin inhibitors has not been established rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including pimecrolimus cream, 1% continuous long-term use of topical calcineurin inhibitors, including pimecrolimus cream, 1%, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis pimecrolimus cream, 1% is not indicated for use in children less than 2 years of age should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis should not be used in patients with Netherton’s Syndrome or skin diseases with a potential for increased systemic absorption Pregnancy & Lactation pimecrolimus cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother Side Effects application site burning headache nasopharyngitis cough influenza pyrexia viral infection rare cases of malignancy (e.g., skin and lymphoma)
Pimecrolimus Rx cream Actavis Pharma, Inc.	Popularity – score 100 out of 100 (most-viewed drug)	7 warnings	2 pregnancy and lactation warnings	8 side effects	Trend: fell 18% over 11 months; peaks in May, Aug, Oct, Nov, Feb.
Pimecrolimus® · First marketed 2018 · Label last revised May 7, 2018View full label details → Warnings The long-term safety of topical calcineurin inhibitors has not been established, so it's important to be cautious. There have been rare cases of malignancy (such as skin cancer and lymphoma) reported in patients treated with topical calcineurin inhibitors, including pimecrolimus cream, 1%. You should avoid continuous long-term use of topical calcineurin inhibitors, including pimecrolimus cream, 1%, in any age group, and limit application to areas affected by atopic dermatitis. Pimecrolimus cream, 1% is not recommended for use in children under 2 years of age. This medication should not be used in immunocompromised adults and children, including those on systemic immunosuppressive medications. Please avoid using this treatment on malignant or pre-malignant skin conditions, as these can appear as dermatitis. You should not use this medication if you have Netherton’s Syndrome or skin diseases that may lead to increased systemic absorption. Pregnancy & Lactation You should use pimecrolimus cream, 1%, during pregnancy only if the potential benefits outweigh the potential risks to your fetus. You and your healthcare provider should decide whether to continue nursing or to stop the medication, considering how important the drug is for you. Side Effects You may experience a burning sensation at the application site. You might have a headache. You could develop nasopharyngitis. Coughing may occur. You may catch the flu. You might experience a fever. You could be at risk for a viral infection. In rare cases, there may be a risk of malignancy, such as skin cancer or lymphoma. Warnings long-term safety of topical calcineurin inhibitors has not been established rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including pimecrolimus cream, 1% continuous long-term use of topical calcineurin inhibitors, including pimecrolimus cream, 1%, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis pimecrolimus cream, 1% is not indicated for use in children less than 2 years of age should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis should not be used in patients with Netherton’s Syndrome or skin diseases with a potential for increased systemic absorption Pregnancy & Lactation pimecrolimus cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother Side Effects application site burning headache nasopharyngitis cough influenza pyrexia viral infection rare cases of malignancy (e.g., skin and lymphoma)

Data Generation & Sources

This page was automatically generated and is maintained by the AllDrugs AI Data-Science Team. It was built from the FDA Structured Product Label (DailyMed) for products containing Pimecrolimus (UNII: 7KYV510875), retrieved March 4, 2026 by a validated AI data-extraction workflow. Complete dosage-form information for each product is available on its individual label page. Regulatory status, pharmacologic class (EPC), and mechanism of action (MoA) were cross-checked against the FDA Orange Book. No human clinician has reviewed this version.

Learn more in our Editorial Policy

Last AI update: March 4, 2026

Primary FDA sources:

Drug labels referenced:

Regulatory data notice: Information on this page is reproduced verbatim from FDA public databases (NSDE, Orange Book, Purple Book, DailyMed SPL). NDA/ANDA drugs are FDA-approved, BLA biologics are FDA-licensed. Inclusion alone does not guarantee current market availability or imply FDA endorsement.

Medical disclaimer: This AI-generated content is provided for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional for diagnosis or treatment decisions.